The proposed bill introduces the criminal offense of "Prescription Drug Harm or Homicide" to the Arkansas Code, specifically under a new section 5-63-206. This offense applies to executive officers of pharmaceutical companies who, while being 18 years or older, introduce a prescription drug into the market and knowingly conceal information about its dangerous effects. If the drug is prescribed and subsequently causes death or serious injury to a user, the executive officer can be charged with this unclassified felony, which carries a potential prison sentence of one year to life.

Additionally, the bill establishes the "Prescription Drug Harm or Homicide Offense Fund" under section 19-5-1287, which will be funded through federal grants, appropriations from the General Assembly, and other authorized revenues. The Attorney General is tasked with utilizing this fund to support the prosecution of the newly defined offense. The act is set to expire on December 31, 2026, at which point the relevant sections may be removed from the Arkansas Code, and any remaining funds in the offense fund will be transferred to the General Revenue Fund Account.